A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY, COMPARING THE EFFICACY AND SAFETY OF REMIBRUTINIB VERSUS TERIFLUNOMIDE IN PARTICIPANTS WITH RELAPSING MULTIPLE SCLEROSIS, FOLLOWED BY EXTENDED TREATMENT WITH OPEN-LABEL REMIBRUTINIB

Registry ID

CLOU064C12302

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

NOVARTIS PHARMACEUTICALS CANADA INC

Start date

2022-09-12

Last update

2021-12-29

Conditions

• RELAPSING-REMITTING MULTIPLE SCLEROSIS

Related clinical trials

• AN OPEN-LABEL, SINGLE ARM, MULTI-CENTER EXTENSION STUDY EVALUATING LONG-TERM SAFETY, TOLERABILITY AND EFFECTIVENESS OF OFATUMUMAB IN SUBJECTS WITH RELAPSING MULTIPLE SCLEROSIS
• AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH EARLY STAGE RELAPSING REMITTING MULTIPLE SCLEROSIS
• A PHASE 3B, 12-MONTH, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIIB019, DACLIZUMAB, IN SUBJECTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) SWITCHING FROM NATALIZUMAB (SUSTAIN)

View on source registry